NCT06472531View on ClinicalTrials.gov

A Study of PET/CT Imaging Using INR101 Injection in Healthy Male Subjects and Patients With Suspected Prostate Cancer

PHASE1/PHASE2CompletedINTERVENTIONAL
Enrollment

32

Participants

Timeline

Start Date

May 23, 2024

Primary Completion Date

September 30, 2024

Study Completion Date

October 10, 2024

Conditions
Healthy Male SubjectsSuspected Prostate Cancer
Interventions
DRUG

INR101

• 9±1 mCi of INR101 will be injected intravenously prior to perform the PET/CT

DRUG

INR101

"* 9±1 mCi of INR101 will be injected intravenously prior to perform the PET/CT~* 7±1 mCi of INR101 will be injected intravenously prior to perform the PET/CT"

Trial Locations (1)

100088

Yunhe Pharmaceutical (Tianjin) Co., Ltd., Tianjin

All Listed Sponsors
lead

Yunhe Pharmaceutical (Tianjin) Co., Ltd

OTHER

NCT06472531 - A Study of PET/CT Imaging Using INR101 Injection in Healthy Male Subjects and Patients With Suspected Prostate Cancer | Biotech Hunter | Biotech Hunter